{
    "id": 26983,
    "fullName": "CDH6 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CDH6 positive indicates the presence of the CDH6 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1004,
        "geneSymbol": "CDH6",
        "terms": [
            "CDH6",
            "CAD6",
            "KCAD"
        ]
    },
    "variant": "positive",
    "createDate": "09/11/2017",
    "updateDate": "01/03/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11886,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, HKT288 treatment induced tumor regression in 2 patient-derived xenograft (PDX) models of ovarian cancer with heterogeneous CDH6 expression, and resulted in an response rate of 40% (12/30) in unselected models in an ovarian cancer PDX clinical trial, with a positive correlation between CDH6 expression and response, and a response rate of 64% (9/14) in models expressing median or greater levels of CDH6 (PMID: 28526733).",
            "molecularProfile": {
                "id": 28334,
                "profileName": "CDH6 positive"
            },
            "therapy": {
                "id": 6198,
                "therapyName": "HKT288",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9886,
                    "pubMedId": 28526733,
                    "title": "Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28526733"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11884,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, HKT288 induced tumor regression in a CDH6-positive ovarian serous carcinoma cell line xenograft model (PMID: 28526733).",
            "molecularProfile": {
                "id": 28334,
                "profileName": "CDH6 positive"
            },
            "therapy": {
                "id": 6198,
                "therapyName": "HKT288",
                "synonyms": null
            },
            "indication": {
                "id": 50933,
                "name": "ovarian serous carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9886,
                    "pubMedId": 28526733,
                    "title": "Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28526733"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28334,
            "profileName": "CDH6 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}